Drug Profile
Revatropate
Alternative Names: UK 112166; UK 112166-04Latest Information Update: 21 Mar 2000
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antiasthmatics; Bronchodilators; Quinuclidines; Small molecules
- Mechanism of Action Muscarinic M1 receptor antagonists; Muscarinic M3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 21 Mar 2000 No-Development-Reported for Chronic obstructive pulmonary disease in European Union (Inhalation)
- 25 Sep 1997 New profile
- 25 Sep 1997 Phase-II clinical trials for Chronic obstructive pulmonary disease in European Union (Inhalation)